PD-L1/CD47 TUMOR DIRECTED B-BODYTM BISPECIFIC ANTIBODIES DEMONSTRATING SIGNIFICANT ANTITUMOR ACTIVITY WITH NO TOXICITY IN PRECLINICAL MODELS

被引：0
|
作者：
Kantak, Seema [1 ]
Glaser, Bryan [2 ]
Wetter, Justin [2 ]
Sim, Bee-Cheng [1 ]
Higaki, Jeff [1 ]
Beal, Jacob [2 ]
Ollerman, Sara [2 ]
Pulukkunat, Dileep [2 ]
Bawadekar, Mandar [2 ]
Kaplan, Charles [1 ]
Lamb, Peter [1 ]
Hammer, Bonnie [2 ]
机构：
[1] Exelixis Inc, Alameda, CA USA
[2] Invenra Inc, Madison, WI USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2020年 / 8卷
关键词：
D O I：
10.1136/jitc-2020-SITC2020.0630
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
630
引用
收藏
页码：A378 / A378
页数：1
相关论文
共 50 条
  • [31] Phase 1 first-in-human study of PF-07257876, a novel CD47/PD-L1 bispecific checkpoint inhibitor, in patients with PD-1/PD-L1-refractory and -naive advanced solid tumors
    Carneiro, Benedito A.
    Safran, Howard
    Beck, J. Thaddeus Thaddeus
    Hamid, Omid
    Spira, Alexander I.
    Savvides, Panos
    Gutierrez, Martin
    Zhao, Yujie
    Abbruzzese, James L.
    Ward, Jeffrey P.
    Weroha, Saravut John
    Harris, Loleta D.
    Kent, Sean
    Pierceall, William
    Skoura, Athanasia
    Zheng, Jenny
    Kern, Kenneth Alan
    Thomas, Jacob Stephen
    Santana-Davila, Rafael
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [32] The expression of PD-L1 on tumor-derived exosomes enhances infiltration and anti-tumor activity of αCD3 x αPD-L1 bispecific antibody-armed T cells
    Cho, Jaewon
    Tae, Nara
    Song, Yujeong
    Kim, Chae-Won
    Lee, Seung-Joo
    Ahn, Jae-Hee
    Lee, Kwang-Ho
    Lee, Byung-Hyun
    Kim, Byung Soo
    Chang, Sun-Young
    Kim, Dae Hee
    Ko, Hyun-Jeong
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (10)
  • [33] Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity
    Sam, Johannes
    Colombetti, Sara
    Fauti, Tanja
    Roller, Andreas
    Biehl, Marlene
    Fahrni, Linda
    Nicolini, Valeria
    Perro, Mario
    Nayak, Tapan
    Bommer, Esther
    Schoenle, Anne
    Karagianni, Maria
    Le Clech, Marine
    Steinhoff, Nathalie
    Klein, Christian
    Umana, Pablo
    Bacac, Marina
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [34] Dual blockage of both PD-L1 and CD47 enhances the therapeutic effect of oxaliplatin and FOLFOX in CT-26 mice tumor model
    Alimohammadi, Reza
    Chalbatani, Ghanbar Mahmoodi
    Alimohammadi, Masoumeh
    Ghaffari-Nazari, Haniyeh
    Rahimi, Arezou
    Mortaz, Esmail
    Mossafa, Nariman
    Boon, Louis
    Jalali, Seyed Amir
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [35] Role of the expression of PD-L1 and CD47 on circulating tumor cells (CTCs) in the prediction of outcome in metastatic breast cancer (mBC) patients.
    Agelaki, Sofia
    Papadaki, Maria A.
    Tsoulfas, Panormitis G.
    Aggouraki, Despoina
    Monastirioti, Alexia A.
    Merodoulaki, Katerina A.
    Thomopoulou, Konstantina
    Papadaki, Chara
    Mavroudis, Dimitrios
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [36] Dual blockage of both PD-L1 and CD47 enhances the therapeutic effect of oxaliplatin and FOLFOX in CT-26 mice tumor model
    Reza Alimohammadi
    Ghanbar Mahmoodi Chalbatani
    Masoumeh Alimohammadi
    Haniyeh Ghaffari-Nazari
    Arezou Rahimi
    Esmail Mortaz
    Nariman Mossafa
    Louis Boon
    Seyed Amir Jalali
    Scientific Reports, 13
  • [37] CD24, not CD47, negatively impacts upon response to PD-1/L1 inhibitors in non-small-cell lung cancer with PD-L1 tumor proportion score < 50
    Ozawa, Yuichi
    Harutani, Yuhei
    Oyanagi, Jun
    Akamatsu, Hiroaki
    Murakami, Eriko
    Shibaki, Ryota
    Hayata, Atsushi
    Sugimoto, Takeya
    Tanaka, Masanori
    Takakura, Toshiaki
    Furuta, Katsuyuki
    Okuda, Yuka
    Sato, Kouichi
    Teraoka, Shunsuke
    Ueda, Hiroki
    Tokudome, Nahomi
    Kitamura, Yuka
    Fukuoka, Junya
    Nakanishi, Masanori
    Koh, Yasuhiro
    Yamamoto, Nobuyuki
    CANCER SCIENCE, 2021, 112 (01) : 72 - 80
  • [38] An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity
    Cheng, Lian-sheng
    Zhu, Min
    Gao, Yan
    Liu, Wen-ting
    Yin, Wu
    Zhou, Pengfei
    Zhu, Zhongliang
    Niu, Liwen
    Zeng, Xiaoli
    Zhang, Dayan
    Fang, Qing
    Wang, Fengrong
    Zhao, Qun
    Zhang, Yan
    Shen, Guodong
    CELLULAR & MOLECULAR BIOLOGY LETTERS, 2023, 28 (01)
  • [39] HX009, a novel BsAb dual targeting PD1 x CD47, demonstrates potent anti-lymphoma activity in preclinical models
    Ke, Hang
    Zhang, Faming
    Wang, Jingjing
    Xiong, Lingxin
    An, Xiaoyu
    Tu, Xiaolong
    Chen, Cen
    Wang, Yueying
    Mao, Binchen
    Guo, Sheng
    Ju, Cunxiang
    He, Xiangfei
    Sun, Ruilin
    Zhang, Lei
    O'Connor, Owen A.
    Li, Qi-Xiang
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [40] An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity
    Lian-sheng Cheng
    Min Zhu
    Yan Gao
    Wen-ting Liu
    Wu Yin
    Pengfei Zhou
    Zhongliang Zhu
    Liwen Niu
    Xiaoli Zeng
    Dayan Zhang
    Qing Fang
    Fengrong Wang
    Qun Zhao
    Yan Zhang
    Guodong Shen
    Cellular & Molecular Biology Letters, 28
12345